Search 

Jaleva Pharmaceuticals is a company focused on the improved delivery of active ingredients to the skin or mucosa.  We achieve this with our Patented Resin technology, and do so topically, and transmucosally.  The core of our Delivery is fast acting, and long lasting delivery of API's.

We currently have three products ready for license.  

1. A Surgical Prep product to compete with Chloraprep.

2. A Topical Pain Relief Spray, for two times a day use.

3. An NRT Trans-buccal product, quick acting, mimicking the craving reduction of a cigarette.

We have an array of other products in our development pipeline.  

JRX Biotech is focused on (1) pain management and (2) dermatology applications.  We are a post revenue specialty biochemistry technology company.

We develop topical products using our patented delivery system platform (formfactors: liquid solutions, serums, lotions, creams, sprays).

DermX Megasphere Delivery System -- a dermal/transdermal delivery system technology platform that has been independently proven to allow high payloads of large molecular weight molecules to passively penetrate into and through human skin.

DermX Features / Benefits:

  --Passive, topical solution

  --Patented

  --Proven (Franz Cell and in vivo)

  --High payloads delivered (>20% of the applied dose penetrating)

  --Large molecules delivered (>11kD)

  --No irritation

We are looking to:

  (1) Co-develop our lead topical pain relief patented product (first-in-class).

  (2) Co-develop our pipeline of patented topical pain relief products.

  (3) Out-license our platform delivery system technology.

Keystone Nano (KN) is a developing two nanotechnology platforms to solve problems in the treatment of cancer. Both the Ceramide NanoLiposome (CNL) and the NanoJacket (NJ) precisely deliver therapies to tumors and address a $50 billion cancer therapeutic market where single products routinely exceed a billion in sales. KN’s technology was licensed from Penn State, and is distinct from all technology in development and has substantial technological advantages.  KN technology is an advanced stage of development is supported by considerable intellectual property and a successful multi-disciplinary commercialization team.

KN also creates custom nanoparticles for client companies designed to allow the creation of new products of value with highly unique features.  KN has worked with a wide range of pharmaceutical clients in this manner, and can do so in a milestone based manner.

Kimberly-Clark has developed an innovative transdermal drug delivery technology for Biologics.  The Biologic Transdermal System is designed to deliver large molecular weight biologics (demonstrated up to 150,000 Daltons) without a pump or other secondary device.   Kimberly-Clark has a rich heritage of providing innovative, high quality products for both consumer and B2B markets, including its $1.5 billion healthcare division that manufactures and markets a broad range of medical devices and medical supplies.

MacroGenics is a leader in the development of next-generation antibody therapeutics for the treatment of cancer, autoimmune disorders, and infectious disease. Using its proprietary platforms for cancer-stem cells, bi-specific antibodies (DARTs) and Fc-optimization, the company has generated a robust pipeline of clinical and pre-clinical programs. The company has multiple research and development collaborations with major pharmaceutical companies including Les Laboratoires Servier, Boehringer Ingelheim and Pfizer, Inc.

MannKind’s patient-focused oral inhalation drug delivery technologies include a dry powder formulation capability coupled with an innovative, elegant, breath-powered delivery device. We are applying these technologies to facilitate partnered drug development programs for proprietary compounds.

MannKind has numerous collaborations across therapeutic areas that demonstrate the efficacy and safety of the technologies. Patients self-administer these dry powder formulations with small, easy-to-use, breath-powered inhalers. Following inhalation, drugs are absorbed very rapidly, essentially mimicking intra-arterial administration. MannKind has evaluated this versatile pulmonary drug delivery platform across multiple therapeutic areas, including diabetes, metabolism, respiratory disease, osteoporosis and pain.

For companies interested in exploring the feasibility of a Technosphere formulation using their own active pharmaceutical ingredient (API), MannKind offers a feasibility evaluation. These evaluations involve preparation and characterization of API/Technosphere formulations. These powders are tested for performance in MannKind’s inhalers. Additionally, MannKind works with the partner to test these powders in relevant nonclinical PK/PD models. These studies can often been completed within 6 months. 

MannKind seeks to establish partnerships to build therapeutic programs of significant clinical and commercial value. Whether through strategic alliances, licensing arrangements and/or research collaborations, MannKind's partnering approach is based on a flexible, creative methodology designed to establish mutually beneficial relationships that are positioned to capture upside potential beyond what either partner could achieve individually.

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration (FDA) reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete Response letter with respect to this NDA. MAP Pharmaceuticalshas entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com.

Metanomics Health, a BASF group company, is the world leading company offering targeted and non-targeted metabolite profiling to healthcare customers in industry and academia. We serve pharma, nutrition and diagnostics customers, making them more successful through biomarker identification and validation across a broad range of applications.

In parallel to our third party service business we are funding and conducting a comprehensive diagnostic biomarker program in the areas of cardio-metabolic diseases, multiple sclerosis and various oncology indications, addressing open questions of high and unmet medical need.

Biomarkers covering disease diagnosis, mechanism of drug toxicity, mechanism of action and drug efficacy are increasingly needed in the preclinical and clinical setting for better evaluation of novel chemical entities including target validation and tailor-made treatment regimens.

Our non-biased broad profiling platform as well as the hypothesis-driven targeted metabolomics platforms have the potential for providing novel biomarkers of disease and drug efficacy and are routinely incorporated into biomarker discovery and validation studies.

We enhance contextualization of our reproducible and robust metabolic signatures via integration with data from other “-omics” platforms such as transcriptomics or proteomics. In our systems biology approach we are linking known metabolites and genes to relevant pathways and phenotypes, i.e. mapping genotype to phenotype.

Our customers´ personalized medicines and nutrition solutions are guided by differentiated and robust metabolite biomarker signatures, thus making sure that the right intervention is selected for the right person at the right time.